ALNY vs. TEM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALNY and TEM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ALNY | TEM |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Tempus AI, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 60.39 billion USD | 12.05 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | June 1, 2004 | June 14, 2024 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ALNY and TEM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ALNY | TEM |
|---|---|---|
| 5-Day Price Return | 1.69% | -4.60% |
| 13-Week Price Return | 0.06% | -7.18% |
| 26-Week Price Return | 68.31% | -0.62% |
| 52-Week Price Return | 69.75% | 0.59% |
| Month-to-Date Return | -1.51% | -23.78% |
| Year-to-Date Return | 90.88% | 102.84% |
| 10-Day Avg. Volume | 0.97M | 7.32M |
| 3-Month Avg. Volume | 1.14M | 8.96M |
| 3-Month Volatility | 30.24% | 66.82% |
| Beta | 0.30 | 2.31 |
Profitability
Return on Equity (TTM)
ALNY
-274.21%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
ALNY has a negative Return on Equity of -274.21%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
TEM
-67.96%
Life Sciences Tools & Services Industry
- Max
- 23.81%
- Q3
- 11.79%
- Median
- 7.51%
- Q1
- 3.14%
- Min
- -6.95%
TEM has a negative Return on Equity of -67.96%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
ALNY
-12.96%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
ALNY has a negative Net Profit Margin of -12.96%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
TEM
-18.45%
Life Sciences Tools & Services Industry
- Max
- 33.77%
- Q3
- 17.97%
- Median
- 8.97%
- Q1
- 3.80%
- Min
- -11.89%
TEM has a negative Net Profit Margin of -18.45%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
ALNY
-7.32%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
ALNY has a negative Operating Profit Margin of -7.32%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
TEM
-23.00%
Life Sciences Tools & Services Industry
- Max
- 31.55%
- Q3
- 21.26%
- Median
- 14.06%
- Q1
- 8.54%
- Min
- 0.11%
TEM has a negative Operating Profit Margin of -23.00%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | ALNY | TEM |
|---|---|---|
| Return on Equity (TTM) | -274.21% | -67.96% |
| Return on Assets (TTM) | -7.41% | -12.79% |
| Net Profit Margin (TTM) | -12.96% | -18.45% |
| Operating Profit Margin (TTM) | -7.32% | -23.00% |
| Gross Profit Margin (TTM) | 83.64% | 61.73% |
Financial Strength
Current Ratio (MRQ)
ALNY
2.80
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
ALNY’s Current Ratio of 2.80 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
TEM
3.28
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.87
- Median
- 1.75
- Q1
- 1.37
- Min
- 0.57
TEM’s Current Ratio of 3.28 is in the upper quartile for the Life Sciences Tools & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
ALNY
4.10
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 4.10, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
TEM
2.45
Life Sciences Tools & Services Industry
- Max
- 0.95
- Q3
- 0.70
- Median
- 0.45
- Q1
- 0.18
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.45, TEM operates with exceptionally high leverage compared to the Life Sciences Tools & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
ALNY
-0.95
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
ALNY has a negative Interest Coverage Ratio of -0.95. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
TEM
-14.08
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
TEM has a negative Interest Coverage Ratio of -14.08. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | ALNY | TEM |
|---|---|---|
| Current Ratio (MRQ) | 2.80 | 3.28 |
| Quick Ratio (MRQ) | 2.63 | 3.00 |
| Debt-to-Equity Ratio (MRQ) | 4.10 | 2.45 |
| Interest Coverage Ratio (TTM) | -0.95 | -14.08 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
TEM
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.02%
- Q3
- 0.67%
- Median
- 0.32%
- Q1
- 0.00%
- Min
- 0.00%
TEM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
TEM
0.00%
Life Sciences Tools & Services Industry
- Max
- 97.67%
- Q3
- 61.34%
- Median
- 18.53%
- Q1
- 0.00%
- Min
- 0.00%
TEM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ALNY | TEM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ALNY
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for ALNY is currently unavailable.
TEM
--
Life Sciences Tools & Services Industry
- Max
- 78.22
- Q3
- 57.42
- Median
- 34.18
- Q1
- 28.39
- Min
- 1.55
P/E Ratio data for TEM is currently unavailable.
Price-to-Sales Ratio (TTM)
ALNY
24.10
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
ALNY’s P/S Ratio of 24.10 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
TEM
10.69
Life Sciences Tools & Services Industry
- Max
- 10.69
- Q3
- 6.37
- Median
- 4.95
- Q1
- 3.27
- Min
- 1.04
TEM’s P/S Ratio of 10.69 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
ALNY
169.67
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
At 169.67, ALNY’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
TEM
27.61
Life Sciences Tools & Services Industry
- Max
- 8.12
- Q3
- 5.04
- Median
- 3.94
- Q1
- 2.12
- Min
- 1.13
At 27.61, TEM’s P/B Ratio is at an extreme premium to the Life Sciences Tools & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | ALNY | TEM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | -- |
| Price-to-Sales Ratio (TTM) | 24.10 | 10.69 |
| Price-to-Book Ratio (MRQ) | 169.67 | 27.61 |
| Price-to-Free Cash Flow Ratio (TTM) | 331.60 | -- |